IN RE: Xarelto (Rivaroxaban) Products Liability Litigation

  1. September 20, 2019

    J&J's Litigation Bravado In Sharp Relief After Epic Opioid Trial

    Johnson & Johnson's decision this year to risk a $17 billion penalty in the nation's first opioid-crisis trial added one of the most dramatic chapters yet to the company's increasingly remarkable willingness to spurn settlements and litigate financially perilous cases all the way.

  2. December 12, 2014

    Xarelto Safety Suits Sent To Louisiana By MDL Panel

    The U.S. Judicial Panel on Multidistrict Litigation decided Friday to consolidate in Louisiana federal court nearly two dozen suits against Johnson & Johnson unit Janssen Pharmaceuticals Inc. and Bayer Corp. over the blood thinner Xarelto, finding that the cases have enough common factual questions to warrant centralization.